171 related articles for article (PubMed ID: 25879833)
1. Mapping the EQ-5D index from the cystic fibrosis questionnaire-revised using multiple modelling approaches.
Acaster S; Pinder B; Mukuria C; Copans A
Health Qual Life Outcomes; 2015 Mar; 13():33. PubMed ID: 25879833
[TBL] [Abstract][Full Text] [Related]
2. Mapping function from FACT-B to EQ-5D-5 L using multiple modelling approaches: data from breast cancer patients in China.
Yang Q; Yu XX; Zhang W; Li H
Health Qual Life Outcomes; 2019 Oct; 17(1):153. PubMed ID: 31615531
[TBL] [Abstract][Full Text] [Related]
3. Mapping the SRS-22r questionnaire onto the EQ-5D-5L utility score in patients with adolescent idiopathic scoliosis.
Wong CKH; Cheung PWH; Samartzis D; Luk KD; Cheung KMC; Lam CLK; Cheung JPY
PLoS One; 2017; 12(4):e0175847. PubMed ID: 28414745
[TBL] [Abstract][Full Text] [Related]
4. Mapping the COPD Assessment Test onto EQ-5D.
Hoyle CK; Tabberer M; Brooks J
Value Health; 2016 Jun; 19(4):469-77. PubMed ID: 27325339
[TBL] [Abstract][Full Text] [Related]
5. Mapping ALSFRS-R and ALSUI to EQ-5D in Patients with Motor Neuron Disease.
Moore A; Young CA; Hughes DA
Value Health; 2018 Nov; 21(11):1322-1329. PubMed ID: 30442280
[TBL] [Abstract][Full Text] [Related]
6. Generating EQ-5D-3L Utility Scores from the Dermatology Life Quality Index: A Mapping Study in Patients with Psoriasis.
Davison NJ; Thompson AJ; Turner AJ; Longworth L; McElhone K; Griffiths CEM; Payne K;
Value Health; 2018 Aug; 21(8):1010-1018. PubMed ID: 30098665
[TBL] [Abstract][Full Text] [Related]
7. Converting Parkinson-Specific Scores into Health State Utilities to Assess Cost-Utility Analysis.
Chen G; Garcia-Gordillo MA; Collado-Mateo D; Del Pozo-Cruz B; Adsuar JC; Cordero-Ferrera JM; Abellán-Perpiñán JM; Sánchez-Martínez FI
Patient; 2018 Dec; 11(6):665-675. PubMed ID: 29876865
[TBL] [Abstract][Full Text] [Related]
8. Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D.
Hawton A; Green C; Telford C; Zajicek J; Wright D
Value Health; 2012 Dec; 15(8):1084-91. PubMed ID: 23244811
[TBL] [Abstract][Full Text] [Related]
9. Mapping EQ-5D utility scores from the PedsQL™ generic core scales.
Khan KA; Petrou S; Rivero-Arias O; Walters SJ; Boyle SE
Pharmacoeconomics; 2014 Jul; 32(7):693-706. PubMed ID: 24715604
[TBL] [Abstract][Full Text] [Related]
10. Development of the Cystic Fibrosis Questionnaire-Revised-8 Dimensions: Estimating Utilities From the Cystic Fibrosis Questionnaire-Revised.
Acaster S; Mukuria C; Rowen D; Brazier JE; Wainwright CE; Quon BS; Duckers J; Quittner AL; Lou Y; Sosnay PR; McGarry LJ
Value Health; 2023 Apr; 26(4):567-578. PubMed ID: 36509366
[TBL] [Abstract][Full Text] [Related]
11. Mapping study of papillary thyroid carcinoma in China: Predicting EQ-5D-5L utility values from FACT-H&N.
Huang D; Peng J; Chen N; Yang Q; Jiang L
Front Public Health; 2023; 11():1076879. PubMed ID: 36908441
[TBL] [Abstract][Full Text] [Related]
12. Predicting EQ-5D utility scores from the Seattle Angina Questionnaire in coronary artery disease: a mapping algorithm using a Bayesian framework.
Wijeysundera HC; Tomlinson G; Norris CM; Ghali WA; Ko DT; Krahn MD
Med Decis Making; 2011; 31(3):481-93. PubMed ID: 21127316
[TBL] [Abstract][Full Text] [Related]
13. Development of algorithms to estimate the EQ-5D-5L from the FACT-L in patients with lung cancer: a mapping study.
Jiang L; Zhou H; Yang Q; Luo X; Huang D
Qual Life Res; 2024 Mar; 33(3):805-816. PubMed ID: 38148367
[TBL] [Abstract][Full Text] [Related]
14. Mapping of the EORTC QLQ-C30 to EQ-5D-5L index in patients with lymphomas.
Xu RH; Wong ELY; Jin J; Dou Y; Dong D
Eur J Health Econ; 2020 Dec; 21(9):1363-1373. PubMed ID: 32960388
[TBL] [Abstract][Full Text] [Related]
15. Mapping the 25-item National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) to EQ-5D utility scores.
Kay S; Ferreira A
Ophthalmic Epidemiol; 2014 Apr; 21(2):66-78. PubMed ID: 24568628
[TBL] [Abstract][Full Text] [Related]
16. Mapping analysis to estimate EQ-5D utility values using the COPD assessment test in Korea.
Lim J; Choi SE; Bae E; Kang D; Lim EA; Shin GS
Health Qual Life Outcomes; 2019 Jun; 17(1):97. PubMed ID: 31170982
[TBL] [Abstract][Full Text] [Related]
17. Cross-sectional validity of the EQ-5D-Y as a generic health outcome instrument in children and adolescents with cystic fibrosis in Germany.
Eidt-Koch D; Mittendorf T; Greiner W
BMC Pediatr; 2009 Aug; 9():55. PubMed ID: 19715563
[TBL] [Abstract][Full Text] [Related]
18. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
Kontodimopoulos N; Aletras VH; Paliouras D; Niakas D
Value Health; 2009; 12(8):1151-7. PubMed ID: 19558372
[TBL] [Abstract][Full Text] [Related]
19. Mapping PedsQL™ Generic Core Scales to EQ-5D-3L utility scores in transfusion-dependent thalassemia patients.
Shafie AA; Chhabra IK; Wong JHY; Mohammed NS
Eur J Health Econ; 2021 Jul; 22(5):735-747. PubMed ID: 33860379
[TBL] [Abstract][Full Text] [Related]
20. Bayesian statistical models to estimate EQ-5D utility scores from EORTC QLQ data in myeloma.
Kharroubi SA; Edlin R; Meads D; McCabe C
Pharm Stat; 2018 Jul; 17(4):358-371. PubMed ID: 29460413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
